Biocon hits 52-week low as Pfizer scraps deal

Tags: Companies
Shares of Biocon tumbled by over 6 per cent today, as a drug deal of the biotechnology firm with US-based pharmaceutical giant Pfizer was scrapped.

After plunging as much as 11 per cent to touch a 52-week low of Rs 238 in the intra-day trade on the BSE, Biocon shares recovered some of the losses and settled for the day 6.31 per cent down at Rs 250.80.

At the NSE also, the stock closed at Rs 250.85, down 6.24 per cent.

Earlier in the day, Biocon and Pfizer called off their $ 350 million global alliance to commercialise the Bangalore-based firm's biosimilar versions of insulin and insulin analog products.

"The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently," the two firms said in a joint statement.

The fall in Biocon share price was in sharp contrast to an overall rally in the market, where the barometer index Sensex ended 225.95 points up at 17,813.62.

EDITORIAL OF THE DAY

  • Mergers apart, Sebi must also allow fund houses to offer diverse products

    The Securities and Exchange Board of India’s (Sebi’s) reported push for merger of open-ended mutual fund schemes is a logical step, as there is li

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Arun Nigavekar

Can Hefa actually become a reality?

The ministry of human resource development (MHRD) is actively wo­rking ...

Rajgopal Nidamboor

Creativity is that divine luminosity

Creativity or ingenuity, isn’t a licence limited to ‘functioning’ minds ...

Dharmendra Khandal

No one's getting rich overnight by poaching

We often read in newspapers that tiger skin worth Rs ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture